Conditions:   Acute Leukemia;   Chronic Leukemia;   Myelodysplastic Syndrome;   Non-Hodgkins Lymphoma
Intervention:   Drug: CD34+ progenitors on the Clinimacs device
Sponsors:   Memorial Sloan-Kettering Cancer Center;   Memorial Sloan-Kettering Cancer Center
Recruiting - verified May 2012

Condition:   Sickle Cell Disease
Intervention:   Other: Biological: Bone Marrow Transplant
Sponsors:   University of Pittsburgh;   University of Pittsburgh;   National Institutes of Health (NIH);   National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified April 2012

Conditions:   Accelerated Phase Chronic Myelogenous Leukemia;   Adult Acute Lymphoblastic Leukemia in Remission;   Adult Acute Myeloid Leukemia in Remission;   Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Adult Acute Myeloid Leukemia With Del(5q);   Adult Acute Myeloid Leukemia With Inv(16)(p13;q22);   Adult Acute Myeloid Leukemia With t(15;17)(q22;q12);   Adult Acute Myeloid Leukemia With t(16;16)(p13;q22);   Adult Acute Myeloid Leukemia With t(8;21)(q22;q22);   Adult Grade III Lymphomatoid Granulomatosis;   Adult Nasal Type Extranodal NK/T-cell Lymphoma;   Anaplastic Large Cell Lymphoma;   Angioimmunoblastic T-cell Lymphoma;   Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative;   Blastic Phase Chronic Myelogenous Leukemia;   Chronic Eosinophilic Leukemia;   Chronic Myelomonocytic Leukemia;   Chronic Neutrophilic Leukemia;   Chronic Phase Chronic Myelogenous Leukemia;   Contiguous Stage II Adult Burkitt Lymphoma;   Contiguous Stage II Adult Diffuse Large Cell Lymphoma;   Contiguous Stage II Adult Diffuse Mixed Cell Lymphoma;   Contiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma;   Contiguous Stage II Adult Immunoblastic Large Cell Lymphoma;   Contiguous Stage II Adult Lymphoblastic Lymphoma;   Contiguous Stage II Grade 1 Follicular Lymphoma;   Contiguous Stage II Grade 2 Follicular Lymphoma;   Contiguous Stage II Grade 3 Follicular Lymphoma;   Contiguous Stage II Mantle Cell Lymphoma;   Contiguous Stage II Marginal Zone Lymphoma;   Contiguous Stage II Small Lymphocytic Lymphoma;   Cutaneous B-cell Non-Hodgkin Lymphoma;   de Novo Myelodysplastic Syndromes;   Essential Thrombocythemia;   Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue;   Hepatosplenic T-cell Lymphoma;   Intraocular Lymphoma;   Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable;   Nodal Marginal Zone B-cell Lymphoma;   Noncontiguous Stage II Adult Burkitt Lymphoma;   Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma;   Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma;   Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma;   Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma;   Noncontiguous Stage II Adult Lymphoblastic Lymphoma;   Noncontiguous Stage II Grade 1 Follicular Lymphoma;   Noncontiguous Stage II Grade 2 Follicular Lymphoma;   Noncontiguous Stage II Grade 3 Follicular Lymphoma;   Noncontiguous Stage II Mantle Cell Lymphoma;   Noncontiguous Stage II Marginal Zone Lymphoma;   Noncontiguous Stage II Small Lymphocytic Lymphoma;   Noncutaneous Extranodal Lymphoma;   Peripheral T-cell Lymphoma;   Polycythemia Vera;   Previously Treated Myelodysplastic Syndromes;   Primary Myelofibrosis;   Progressive Hairy Cell Leukemia, Initial Treatment;   Recurrent Adult Acute Lymphoblastic Leukemia;   Recurrent Adult Acute Myeloid Leukemia;   Recurrent Adult Burkitt Lymphoma;   Recurrent Adult Diffuse Large Cell Lymphoma;   Recurrent Adult Diffuse Mixed Cell Lymphoma;   Recurrent Adult Diffuse Small Cleaved Cell Lymphoma;   Recurrent Adult Grade III Lymphomatoid Granulomatosis;   Recurrent Adult Hodgkin Lymphoma;   Recurrent Adult Immunoblastic Large Cell Lymphoma;   Recurrent Adult Lymphoblastic Lymphoma;   Recurrent Adult T-cell Leukemia/Lymphoma;   Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma;   Recurrent Grade 1 Follicular Lymphoma;   Recurrent Grade 2 Follicular Lymphoma;   Recurrent Grade 3 Follicular Lymphoma;   Recurrent Mantle Cell Lymphoma;   Recurrent Marginal Zone Lymphoma;   Recurrent Mycosis Fungoides/Sezary Syndrome;   Recurrent Small Lymphocytic Lymphoma;   Refractory Chronic Lymphocytic Leukemia;   Refractory Hairy Cell Leukemia;   Refractory Multiple Myeloma;   Relapsing Chronic Myelogenous Leukemia;   Secondary Acute Myeloid Leukemia;   Secondary Myelodysplastic Syndromes;   Secondary Myelofibrosis;   Small Intestine Lymphoma;   Splenic Marginal Zone Lymphoma;   Stage I Adult Burkitt Lymphoma;   Stage I Adult Diffuse Large Cell Lymphoma;   Stage I Adult Diffuse Mixed Cell Lymphoma;   Stage I Adult Diffuse Small Cleaved Cell Lymphoma;   Stage I Adult Hodgkin Lymphoma;   Stage I Adult Immunoblastic Large Cell Lymphoma;   Stage I Adult Lymphoblastic Lymphoma;   Stage I Adult T-cell Leukemia/Lymphoma;   Stage I Chronic Lymphocytic Leukemia;   Stage I Cutaneous T-cell Non-Hodgkin Lymphoma;   Stage I Grade 1 Follicular Lymphoma;   Stage I Grade 2 Follicular Lymphoma;   Stage I Grade 3 Follicular Lymphoma;   Stage I Mantle Cell Lymphoma;   Stage I Marginal Zone Lymphoma;   Stage I Multiple Myeloma;   Stage I Mycosis Fungoides/Sezary Syndrome;   Stage I Small Lymphocytic Lymphoma;   Stage II Adult Hodgkin Lymphoma;   Stage II Adult T-cell Leukemia/Lymphoma;   Stage II Chronic Lymphocytic Leukemia;   Stage II Cutaneous T-cell Non-Hodgkin Lymphoma;   Stage II Multiple Myeloma;   Stage II Mycosis Fungoides/Sezary Syndrome;   Stage III Adult Burkitt Lymphoma;   Stage III Adult Diffuse Large Cell Lymphoma;   Stage III Adult Diffuse Mixed Cell Lymphoma;   Stage III Adult Diffuse Small Cleaved Cell Lymphoma;   Stage III Adult Hodgkin Lymphoma;   Stage III Adult Immunoblastic Large Cell Lymphoma;   Stage III Adult Lymphoblastic Lymphoma;   Stage III Adult T-cell Leukemia/Lymphoma;   Stage III Chronic Lymphocytic Leukemia;   Stage III Cutaneous T-cell Non-Hodgkin Lymphoma;   Stage III Grade 1 Follicular Lymphoma;   Stage III Grade 2 Follicular Lymphoma;   Stage III Grade 3 Follicular Lymphoma;   Stage III Mantle Cell Lymphoma;   Stage III Marginal Zone Lymphoma;   Stage III Multiple Myeloma;   Stage III Mycosis Fungoides/Sezary Syndrome;   Stage III Small Lymphocytic Lymphoma;   Stage IV Adult Burkitt Lymphoma;   Stage IV Adult Diffuse Large Cell Lymphoma;   Stage IV Adult Diffuse Mixed Cell Lymphoma;   Stage IV Adult Diffuse Small Cleaved Cell Lymphoma;   Stage IV Adult Hodgkin Lymphoma;   Stage IV Adult Immunoblastic Large Cell Lymphoma;   Stage IV Adult Lymphoblastic Lymphoma;   Stage IV Adult T-cell Leukemia/Lymphoma;   Stage IV Chronic Lymphocytic Leukemia;   Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma;   Stage IV Grade 1 Follicular Lymphoma;   Stage IV Grade 2 Follicular Lymphoma;   Stage IV Grade 3 Follicular Lymphoma;   Stage IV Mantle Cell Lymphoma;   Stage IV Marginal Zone Lymphoma;   Stage IV Mycosis Fungoides/Sezary Syndrome;   Stage IV Small Lymphocytic Lymphoma;   T-cell Large Granular Lymphocyte Leukemia;   Testicular Lymphoma;   Untreated Adult Acute Lymphoblastic Leukemia;   Untreated Adult Acute Myeloid Leukemia;   Untreated Hairy Cell Leukemia;   Waldenstrom Macroglobulinemia
Interventions:   Drug: sirolimus;   Drug: tacrolimus;   Biological: rituximab;   Biological: anti-thymocyte globulin;   Other: laboratory biomarker analysis;   Other: flow cytometry
Sponsors:   Barbara Ann Karmanos Cancer Institute;   Barbara Ann Karmanos Cancer Institute;   National Cancer Institute (NCI)
Recruiting - verified October 2011

Conditions:   Refractory Multiple Myeloma;   Stage I Multiple Myeloma;   Stage II Multiple Myeloma;   Stage III Multiple Myeloma
Interventions:   Other: pharmacological study;   Drug: tacrolimus;   Drug: sirolimus;   Biological: anti-thymocyte globulin;   Drug: fludarabine phosphate;   Drug: busulfan;   Drug: bortezomib;   Procedure: allogeneic hematopoietic stem cell transplantation;   Other: laboratory biomarker analysis
Sponsors:   Barbara Ann Karmanos Cancer Institute;   Barbara Ann Karmanos Cancer Institute;   National Cancer Institute (NCI)
Recruiting - verified March 2012

Conditions:   Leukemia;   Lymphoma
Interventions:   Drug: Rituximab;   Drug: 111In Ibritumumab;   Procedure: Planar Scintigraphy Imaging;   Drug: 90Y IbritumumabTiuxetan;   Drug: Fludarabine;   Drug: Bendamustine;   Drug: Thymoglobulin;   Drug: Tacrolimus;   Drug: Methotrexate;   Drug: Mycophenolate;   Drug: G-CSF;   Procedure: Stem Cell Transplantation
Sponsors:   M.D. Anderson Cancer Center;   M.D. Anderson Cancer Center;   Spectrum Pharmaceuticals, Inc
Not yet recruiting - verified May 2012

Conditions:   Disorder Related to Bone Marrow Transplantation;   Leukemia;   Transplantation Infection
Interventions:   Drug: Fludarabine;   Drug: Clofarabine;   Drug: Busulfan;   Drug: Thymoglobulin;   Procedure: Stem Cell Infusion;   Drug: Tacrolimus;   Drug: Methotrexate
Sponsors:   M.D. Anderson Cancer Center;   M.D. Anderson Cancer Center
Recruiting - verified March 2012

Condition:   Scleroderma
Interventions:   Procedure: Rituximab sandwich regiment followed by SCT;   Procedure: cyclophosphamide regiment followed by SCT
Sponsors:   Northwestern University;   Richard Burt, MD
Recruiting - verified April 2012

Conditions:   Accelerated Phase Chronic Myelogenous Leukemia;   Adult Acute Lymphoblastic Leukemia;   Adult Acute Lymphoblastic Leukemia in Remission;   Adult Acute Myeloid Leukemia in Remission;   Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Adult Acute Myeloid Leukemia With Inv(16)(p13;q22);   Adult Acute Myeloid Leukemia With t(15;17)(q22;q12);   Adult Acute Myeloid Leukemia With t(16;16)(p13;q22);   Adult Acute Myeloid Leukemia With t(8;21)(q22;q22);   Adult Grade III Lymphomatoid Granulomatosis;   Adult Nasal Type Extranodal NK/T-cell Lymphoma;   Anaplastic Large Cell Lymphoma;   Angioimmunoblastic T-cell Lymphoma;   Chronic Myelomonocytic Leukemia;   Chronic Phase Chronic Myelogenous Leukemia;   Contiguous Stage II Adult Burkitt Lymphoma;   Contiguous Stage II Adult Diffuse Large Cell Lymphoma;   Contiguous Stage II Adult Diffuse Mixed Cell Lymphoma;   Stage II Adult Diffuse Small Cleaved Cell Lymphoma;   Stage II Adult Immunoblastic Large Cell Lymphoma;   Contiguous Stage II Adult Lymphoblastic Lymphoma;   Contiguous Stage II Grade 1 Follicular Lymphoma;   Contiguous Stage II Grade 2 Follicular Lymphoma;   Contiguous Stage II Grade 3 Follicular Lymphoma;   Contiguous Stage II Mantle Cell Lymphoma;   Cutaneous B-cell Non-Hodgkin Lymphoma;   de Novo Myelodysplastic Syndromes;   Hepatosplenic T-cell Lymphoma;   Intraocular Lymphoma;   Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable;   Nodal Marginal Zone B-cell Lymphoma;   Noncontiguous Stage II Adult Burkitt Lymphoma;   Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma;   Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma;   Noncontiguous Stage II Adult Lymphoblastic Lymphoma;   Noncontiguous Stage II Grade 1 Follicular Lymphoma;   Noncontiguous Stage II Grade 2 Follicular Lymphoma;   Noncontiguous Stage II Grade 3 Follicular Lymphoma;   Noncontiguous Stage II Mantle Cell Lymphoma;   Peripheral T-cell Lymphoma;   Post-transplant Lymphoproliferative Disorder;   Previously Treated Myelodysplastic Syndromes;   Primary Myelofibrosis;   Recurrent Adult Acute Lymphoblastic Leukemia;   Recurrent Adult Acute Myeloid Leukemia;   Recurrent Adult Burkitt Lymphoma;   Recurrent Adult Diffuse Large Cell Lymphoma;   Recurrent Adult Diffuse Mixed Cell Lymphoma;   Recurrent Adult Diffuse Small Cleaved Cell Lymphoma;   Recurrent Adult Grade III Lymphomatoid Granulomatosis;   Recurrent Adult Hodgkin Lymphoma;   Recurrent Adult Immunoblastic Large Cell Lymphoma;   Recurrent Adult Lymphoblastic Lymphoma;   Recurrent Adult T-cell Leukemia/Lymphoma;   Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma;   Recurrent Grade 1 Follicular Lymphoma;   Recurrent Grade 2 Follicular Lymphoma;   Recurrent Grade 3 Follicular Lymphoma;   Recurrent Mantle Cell Lymphoma;   Recurrent Marginal Zone Lymphoma;   Recurrent Mycosis Fungoides/Sezary Syndrome;   Recurrent Small Lymphocytic Lymphoma;   Refractory Chronic Lymphocytic Leukemia;   Refractory Hairy Cell Leukemia;   Small Intestine Lymphoma;   Splenic Marginal Zone Lymphoma;   Stage I Adult Burkitt Lymphoma;   Stage I Adult Diffuse Large Cell Lymphoma;   Stage I Adult Diffuse Mixed Cell Lymphoma;   Stage I Adult Diffuse Small Cleaved Cell Lymphoma;   Stage I Adult Hodgkin Lymphoma;   Stage I Adult Immunoblastic Large Cell Lymphoma;   Stage I Adult Lymphoblastic Lymphoma;   Stage I Adult T-cell Leukemia/Lymphoma;   Stage I Chronic Lymphocytic Leukemia;   Stage I Cutaneous T-cell Non-Hodgkin Lymphoma;   Stage I Grade 1 Follicular Lymphoma;   Stage I Grade 2 Follicular Lymphoma;   Stage I Grade 3 Follicular Lymphoma;   Stage I Mantle Cell Lymphoma;   Stage I Marginal Zone Lymphoma;   Stage I Multiple Myeloma;   Stage I Mycosis Fungoides/Sezary Syndrome;   Stage I Small Lymphocytic Lymphoma;   Stage II Adult Hodgkin Lymphoma;   Stage II Adult T-cell Leukemia/Lymphoma;   Stage II Chronic Lymphocytic Leukemia;   Stage II Cutaneous T-cell Non-Hodgkin Lymphoma;   Stage II Multiple Myeloma;   Stage II Mycosis Fungoides/Sezary Syndrome;   Stage III Adult Burkitt Lymphoma;   Stage III Adult Diffuse Large Cell Lymphoma;   Stage III Adult Diffuse Mixed Cell Lymphoma;   Stage III Adult Diffuse Small Cleaved Cell Lymphoma;   Stage III Adult Hodgkin Lymphoma;   Stage III Adult Immunoblastic Large Cell Lymphoma;   Stage III Adult Lymphoblastic Lymphoma;   Stage III Adult T-cell Leukemia/Lymphoma;   Stage III Chronic Lymphocytic Leukemia;   Stage III Cutaneous T-cell Non-Hodgkin Lymphoma;   Stage III Grade 1 Follicular Lymphoma;   Stage III Grade 2 Follicular Lymphoma;   Stage III Grade 3 Follicular Lymphoma;   Stage III Mantle Cell Lymphoma;   Stage III Marginal Zone Lymphoma;   Stage III Multiple Myeloma;   Stage III Mycosis Fungoides/Sezary Syndrome;   Stage III Small Lymphocytic Lymphoma;   Stage IV Adult Burkitt Lymphoma;   Stage IV Adult Diffuse Large Cell Lymphoma;   Stage IV Adult Diffuse Mixed Cell Lymphoma;   Stage IV Adult Diffuse Small Cleaved Cell Lymphoma;   Stage IV Adult Hodgkin Lymphoma;   Stage IV Adult Immunoblastic Large Cell Lymphoma;   Stage IV Adult Lymphoblastic Lymphoma;   Stage IV Adult T-cell Leukemia/Lymphoma;   Stage IV Chronic Lymphocytic Leukemia;   Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma;   Stage IV Grade 1 Follicular Lymphoma;   Stage IV Grade 2 Follicular Lymphoma;   Stage IV Grade 3 Follicular Lymphoma;   Stage IV Mantle Cell Lymphoma;   Stage IV Marginal Zone Lymphoma;   Stage IV Mycosis Fungoides/Sezary Syndrome;   Stage IV Small Lymphocytic Lymphoma;   T-cell Large Granular Lymphocyte Leukemia;   Testicular Lymphoma;   Waldenstrom Macroglobulinemia
Interventions:   Drug: tacrolimus;   Biological: anti-thymocyte globulin;   Other: laboratory biomarker analysis;   Other: flow cytometry;   Procedure: allogeneic hematopoietic stem cell transplantation;   Procedure: peripheral blood stem cell transplantation
Sponsors:   Barbara Ann Karmanos Cancer Institute;   Barbara Ann Karmanos Cancer Institute
Recruiting - verified April 2012

Condition:   Systemic Scleroderma
Interventions:   Procedure: peripheral blood stem cell transplantation;   Drug: cyclophosphamide;   Biological: anti-thymocyte globulin;   Other: questionnaire administration;   Other: laboratory biomarker analysis;   Procedure: quality-of-life assessment;   Biological: filgrastim;   Procedure: autologous hematopoietic stem cell transplantation
Sponsors:   Fred Hutchinson Cancer Research Center;   Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium;   National Cancer Institute (NCI)
Not yet recruiting - verified March 2012

Conditions:   Leukemia;   Chronic Myelogenous Leukemia
Interventions:   Drug: Fludarabine;   Drug: Busulfan;   Procedure: NK cell infusion:;   Drug: Interleukin-2;   Drug: Anti-Thymocyte Globulin;   Procedure: Allogeneic related Stem Cell Transplant;   Drug: Tacrolimus;   Drug: Methotrexate
Sponsors:   M.D. Anderson Cancer Center;   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
Recruiting - verified April 2012

Conditions:   Neural Tube Defects;   Anemia;   Leukemia, Myeloid;   Bone Marrow Transplant Failure;   Myelodysplastic Syndromes (MDS);   Myeloproliferative Disorders
Interventions:   Drug: CIK cells;   Drug: Cyclosporine;   Drug: Mycophenolate Mofetil;   Drug: Thymoglobulin
Sponsors:   Stanford University;   Stanford University
Recruiting - verified July 2011

Conditions:   Acute Myeloid Leukemia;   Myelodysplastic Syndrome
Interventions:   Drug: Preparative Regimen;   Biological: NK Cell Product;   Drug: Interleukin-2;   Biological: Donor CD34+ Cells;   Biological: Anti-thymocyte globulin
Sponsors:   Masonic Cancer Center, University of Minnesota;   Masonic Cancer Center, University of Minnesota
Recruiting - verified April 2012

Conditions:   Leukemia;   Lymphoma
Interventions:   Procedure: T-Cell Infusion;   Drug: Rituxan;   Drug: Melphalan;   Drug: Thiotepa;   Drug: Fludarabine;   Drug: ATG;   Drug: Cyclophosphamide;   Radiation: Total Body Irradiation (TBI)
Sponsors:   M.D. Anderson Cancer Center;   M.D. Anderson Cancer Center
Not yet recruiting - verified May 2012

Conditions:   Acute Myeloid Leukemia;   Myelodysplastic Syndrome
Intervention:   Drug: Decitabine plus Fludarabine and Busulfan
Sponsors:   Hackensack University Medical Center;   Hackensack University Medical Center
Recruiting - verified October 2011

Condition:   Acute Kidney Injury
Interventions:   Drug: ATG;   Drug: Rituximab;   Drug: Methylprednisolone;   Drug: Diphenhydramine;   Drug: Acetaminophen;   Drug: Tacrolimus;   Drug: Sirolimus;   Drug: Hydrocortisone;   Drug: Prednisone
Sponsors:   National Institute of Allergy and Infectious Diseases (NIAID);   National Institute of Allergy and Infectious Diseases (NIAID);   Immune Tolerance Network (ITN)
Recruiting - verified August 2011

Conditions:   GVHD;   Adult Acute Myeloid Leukemia;   Acute Lymphoid Leukemia;   Myelodysplastic Syndrome
Interventions:   Biological: Anti-human-T-lymphocyte Immune Globulin, Rabbit;   Biological: Placebo
Sponsors:   Fresenius Biotech GmbH;   Fresenius Biotech GmbH;   Fresenius Biotech North America
Recruiting - verified April 2012

Conditions:   Complete DiGeorge Anomaly;   DiGeorge Syndrome;   DiGeorge Anomaly;   Complete DiGeorge Syndrome
Interventions:   Biological: Thymus Transplantation;   Procedure: Blood Draw
Sponsors:   Duke University;   M. Louise Markert;   National Institutes of Health (NIH);   National Institute of Allergy and Infectious Diseases (NIAID);   Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Recruiting - verified February 2012

Conditions:   Leukemia;   Myelodysplastic Syndromes
Interventions:   Biological: anti-thymocyte globulin;   Drug: azacitidine;   Drug: busulfan;   Drug: fludarabine phosphate;   Drug: methotrexate;   Drug: tacrolimus;   Other: laboratory biomarker analysis;   Other: pharmacological study;   Procedure: allogeneic hematopoietic stem cell transplantation
Sponsors:   National Cancer Institute (NCI);   Cancer and Leukemia Group B;   National Cancer Institute (NCI)
Recruiting - verified May 2012

Conditions:   End Stage Renal Disease;   Renal Transplant
Interventions:   Drug: Anti-Thymocyte Globulin;   Drug: TOL101;   Drug: TOL101;   Drug: Steroids;   Drug: Tacrolimus;   Drug: Mycophenolate mofetil (MMF)
Sponsors:   Tolera Therapeutics, Inc;   Tolera Therapeutics, Inc
Recruiting - verified September 2011

Conditions:   Kidney Transplantation;   Renal Transplantation;   Reperfusion Injury
Interventions:   Drug: Myfortic (mycophenolic acid);   Drug: Myfortic (mycophenolic acid);   Drug: Thymoglobulin (anti-thymocyte globulin);   Drug: Thymoglobulin (anti-thymocyte globulin)
Sponsors:   Georgetown University;   Georgetown University;   Novartis
Recruiting - verified October 2011

Condition:   Multiple Myeloma
Interventions:   Drug: busulfan, melphalan and fludarabine;   Drug: busulfan, melphalan and fludarabine
Sponsors:   Memorial Sloan-Kettering Cancer Center;   Memorial Sloan-Kettering Cancer Center;   Otsuka America Pharmaceutical
Recruiting - verified January 2012

Conditions:   Acute Lymphoblastic Leukemia;   Acute Myelogenous Leukemia;   Myelodysplastic Syndrome;   Multiple Myeloma
Interventions:   Device: CliniMACS Fractionation system;   Device: CliniMACS Fractionation system;   Device: CliniMACS Fractionation system
Sponsors:   Memorial Sloan-Kettering Cancer Center;   Memorial Sloan-Kettering Cancer Center
Recruiting - verified December 2011

Conditions:   Chronic Myeloproliferative Disorders;   Graft Versus Host Disease;   Leukemia;   Lymphoma;   Lymphoproliferative Disorder;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Neoplasms
Interventions:   Biological: anti-thymocyte globulin;   Biological: rituximab;   Drug: sirolimus;   Drug: tacrolimus;   Other: laboratory biomarker analysis;   Procedure: allogeneic hematopoietic stem cell transplantation;   Procedure: management of therapy complications;   Procedure: peripheral blood stem cell transplantation
Sponsors:   Barbara Ann Karmanos Cancer Institute;   Barbara Ann Karmanos Cancer Institute;   National Cancer Institute (NCI)
Recruiting - verified March 2012

Condition:   Diabetes Mellitus, Type 1
Interventions:   Drug: Anti-Thymocyte Globin plus pegylated GCSF;   Drug: Placebo
Sponsors:   University of Florida;   University of Florida;   The Helmsley Charitable Trust;   Genzyme
Recruiting - verified February 2012

Conditions:   Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome;   Adult Acute Lymphoblastic Leukemia in Remission;   Adult Acute Megakaryoblastic Leukemia (M7);   Adult Acute Minimally Differentiated Myeloid Leukemia (M0);   Adult Acute Monoblastic Leukemia (M5a);   Adult Acute Monocytic Leukemia (M5b);   Adult Acute Myeloid Leukemia in Remission;   Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Adult Acute Myeloid Leukemia With t(16;16)(p13;q22);   Adult Erythroleukemia (M6a);   Adult Nasal Type Extranodal NK/T-cell Lymphoma;   Adult Pure Erythroid Leukemia (M6b);   B-cell Adult Acute Lymphoblastic Leukemia;   B-cell Childhood Acute Lymphoblastic Leukemia;   Blastic Phase Chronic Myelogenous Leukemia;   Burkitt Lymphoma;   Childhood Acute Erythroleukemia (M6);   Childhood Acute Lymphoblastic Leukemia in Remission;   Childhood Acute Megakaryocytic Leukemia (M7);   Childhood Acute Minimally Differentiated Myeloid Leukemia (M0);   Childhood Acute Monoblastic Leukemia (M5a);   Childhood Acute Monocytic Leukemia (M5b);   Childhood Acute Myeloid Leukemia in Remission;   Childhood Chronic Myelogenous Leukemia;   Childhood Diffuse Large Cell Lymphoma;   Childhood Immunoblastic Large Cell Lymphoma;   Childhood Myelodysplastic Syndromes;   Childhood Nasal Type Extranodal NK/T-cell Lymphoma;   Chronic Myelomonocytic Leukemia;   Chronic Phase Chronic Myelogenous Leukemia;   Cutaneous B-cell Non-Hodgkin Lymphoma;   de Novo Myelodysplastic Syndromes;   Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue;   Juvenile Myelomonocytic Leukemia;   Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable;   Nodal Marginal Zone B-cell Lymphoma;   Previously Treated Myelodysplastic Syndromes;   Prolymphocytic Leukemia;   Recurrent Adult Acute Lymphoblastic Leukemia;   Recurrent Adult Acute Myeloid Leukemia;   Recurrent Adult Burkitt Lymphoma;   Recurrent Adult Diffuse Large Cell Lymphoma;   Recurrent Adult Diffuse Mixed Cell Lymphoma;   Recurrent Adult Diffuse Small Cleaved Cell Lymphoma;   Recurrent Adult Grade III Lymphomatoid Granulomatosis;   Recurrent Adult Immunoblastic Large Cell Lymphoma;   Recurrent Adult Lymphoblastic Lymphoma;   Recurrent Childhood Acute Lymphoblastic Leukemia;   Recurrent Childhood Acute Myeloid Leukemia;   Recurrent Childhood Anaplastic Large Cell Lymphoma;   Recurrent Childhood Grade III Lymphomatoid Granulomatosis;   Recurrent Childhood Large Cell Lymphoma;   Recurrent Childhood Lymphoblastic Lymphoma;   Recurrent Childhood Small Noncleaved Cell Lymphoma;   Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma;   Recurrent Grade 1 Follicular Lymphoma;   Recurrent Grade 2 Follicular Lymphoma;   Recurrent Grade 3 Follicular Lymphoma;   Recurrent Mantle Cell Lymphoma;   Recurrent Marginal Zone Lymphoma;   Recurrent Mycosis Fungoides/Sezary Syndrome;   Recurrent Small Lymphocytic Lymphoma;   Refractory Chronic Lymphocytic Leukemia;   Relapsing Chronic Myelogenous Leukemia;   Secondary Acute Myeloid Leukemia;   Secondary Myelodysplastic Syndromes;   Secondary Myelofibrosis;   Splenic Marginal Zone Lymphoma;   Stage I Chronic Lymphocytic Leukemia;   Stage II Chronic Lymphocytic Leukemia;   Stage III Chronic Lymphocytic Leukemia;   Stage IV Chronic Lymphocytic Leukemia;   T-cell Adult Acute Lymphoblastic Leukemia;   T-cell Childhood Acute Lymphoblastic Leukemia;   T-cell Large Granular Lymphocyte Leukemia;   Waldenstrom Macroglobulinemia
Interventions:   Procedure: double-unit umbilical cord blood transplantation;   Other: cytogenetic analysis;   Procedure: bone marrow aspiration;   Other: fluorescence in situ hybridization;   Drug: busulfan;   Drug: cyclophosphamide;   Drug: anti-thymocyte globulin;   Drug: methylprednisolone;   Drug: cyclosporine;   Drug: mycophenolate mofetil;   Other: flow cytometry;   Procedure: allogeneic hematopoietic stem cell transplantation
Sponsors:   Case Comprehensive Cancer Center;   Case Comprehensive Cancer Center
Recruiting - verified January 2012

Condition:   Epidermolysis Bullosa
Interventions:   Drug: Cyclophosphamide;   Drug: Fludarabine;   Drug: Anti-thymocyte globulin;   Drug: Cyclosporine A;   Drug: Mycophenolate mofetil;   Procedure: Hematopoietic stem cell transplant;   Procedure: Mesenchymal stem cell transplant;   Radiation: Total body irradiation
Sponsors:   Masonic Cancer Center, University of Minnesota;   Masonic Cancer Center, University of Minnesota
Recruiting - verified May 2012

Conditions:   Leukemia;   Lymphoma
Interventions:   Biological: anti-thymocyte globulin;   Biological: rituximab;   Drug: busulfan;   Drug: cyclophosphamide;   Drug: fludarabine phosphate;   Drug: methotrexate;   Drug: sirolimus;   Drug: tacrolimus;   Other: laboratory biomarker analysis;   Procedure: nonmyeloablative allogeneic hematopoietic stem cell transplantation;   Procedure: peripheral blood stem cell transplantation
Sponsors:   National Cancer Institute (NCI);   Cancer and Leukemia Group B;   National Cancer Institute (NCI)
Recruiting - verified May 2012

Conditions:   Leukemia;   Lymphoma;   Allogeneic Haematopoietic Stem Cell Transplantation;   Acute Lymphoblastic Leukemia
Interventions:   Drug: Busulfan;   Drug: Clofarabine;   Drug: Thymoglobulin;   Procedure: Stem Cell Transplant
Sponsors:   M.D. Anderson Cancer Center;   M.D. Anderson Cancer Center
Recruiting - verified March 2012

Conditions:   Bone Marrow Transplantation;   Sickle Cell Disease
Intervention:   Drug: fludarabine
Sponsors:   Emory University;   Emory University
Recruiting - verified November 2011

Conditions:   Anemia, Aplastic;   Anemia, Hypoplastic
Interventions:   Drug: h-ATG (ATGAM(Registered Trademark));   Drug: Cyclosporine (Gengraf(Registered Trademark))
Sponsors:   National Institutes of Health Clinical Center (CC);   National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified April 2012

Conditions:   Leukemia;   Myelodysplastic Syndrome;   Multiple Myeloma;   Lymphoma
Interventions:   Drug: Fludarabine-Melphalan & Rabbit antithymocyte globulin;   Procedure: Stem Cell Transplant;   Procedure: Stem Cells Collections
Sponsors:   University of Chicago;   University of Chicago
Recruiting - verified June 2011

Condition:   Nonmalignant Neoplasm
Interventions:   Procedure: umbilical cord blood transplantation;   Procedure: peripheral blood stem cell transplantation;   Procedure: allogeneic bone marrow transplantation;   Drug: fludarabine phosphate;   Drug: treosulfan;   Radiation: total-body irradiation;   Drug: tacrolimus;   Drug: methotrexate;   Drug: cyclosporine;   Drug: mycophenolate mofetil;   Genetic: DNA analysis;   Other: laboratory biomarker analysis;   Genetic: cytogenetic analysis;   Biological: anti-thymocyte globulin
Sponsors:   Fred Hutchinson Cancer Research Center;   Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium;   National Cancer Institute (NCI);   National Heart, Lung, and Blood Institute (NHLBI);   medac GmbH
Recruiting - verified April 2012

Conditions:   Mycoses;   Sezary Syndrome;   Lymphoma, T-Cell, Cutaneous;   Bone Marrow Transplant Failure;   Lymphoma, Non-Hodgkin;   Cutaneous T-cell Lymphoma of Skin
Interventions:   Drug: anti-thymocyte globulin;   Drug: cyclosporine
Sponsors:   Stanford University;   Stanford University
Recruiting - verified October 2011

Condition:   Chronic Lymphocytic Leukemia
Interventions:   Drug: Lenalidomide;   Drug: Fludarabine;   Drug: Rituximab;   Drug: Thymoglobulin;   Procedure: Stem Cell Transplantation;   Drug: Bendamustine;   Drug: Allopurinol
Sponsors:   M.D. Anderson Cancer Center;   M.D. Anderson Cancer Center;   Celgene Corporation
Recruiting - verified May 2012

Condition:   Lymphoma, Non-Hodgkin
Interventions:   Procedure: Autologous Transplant;   Procedure: Allogeneic Transplant
Sponsors:   Washington University School of Medicine;   Washington University School of Medicine
Recruiting - verified September 2011

Conditions:   Stem Cell Transplantation;   Leukemia;   Lymphoma
Interventions:   Drug: Thiotepa;   Drug: Clofarabine;   Drug: Busulfan;   Procedure: Allogeneic Stem Cell Transplantation;   Drug: Thymoglobulin (ATG);   Drug: G-CSF (Filgrastim)
Sponsors:   M.D. Anderson Cancer Center;   M.D. Anderson Cancer Center
Recruiting - verified February 2012

Conditions:   Chronic Myeloproliferative Disorders;   Fanconi Anemia;   Leukemia;   Lymphoma;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Diseases;   Nonmalignant Neoplasm;   Paroxysmal Nocturnal Hemoglobinuria
Interventions:   Biological: anti-thymocyte globulin;   Biological: graft-versus-tumor induction therapy;   Drug: fludarabine phosphate;   Drug: melphalan;   Procedure: allogeneic hematopoietic stem cell transplantation;   Radiation: total-body irradiation
Sponsors:   Roswell Park Cancer Institute;   Roswell Park Cancer Institute
Recruiting - verified March 2012

Conditions:   Multiple Myeloma;   End Stage Renal Disease
Interventions:   Drug: Cyclophosphamide, anti-thymocyte globulin, cyclosporine;   Procedure: Kidney transplant;   Radiation: Thymic irradiation;   Procedure: Bone marrow transplant from a related donor
Sponsors:   Massachusetts General Hospital;   Massachusetts General Hospital
Recruiting - verified April 2012

Conditions:   Stem Cell Transplantation;   Leukemia
Interventions:   Drug: Fludarabine;   Drug: Busulfan;   Drug: Thymoglobulin;   Drug: Azacitidine;   Procedure: Stem Cell Transplant
Sponsors:   M.D. Anderson Cancer Center;   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
Recruiting - verified December 2011

Condition:   Autoimmune Disorder
Interventions:   Biological: anti-thymocyte globulin;   Drug: carmustine;   Drug: cytarabine;   Drug: etoposide;   Drug: melphalan;   Drug: prednisone;   Procedure: autologous hematopoietic stem cell transplantation;   Procedure: peripheral blood stem cell transplantation;   Procedure: syngeneic bone marrow transplantation;   Other: laboratory biomarker analysis
Sponsors:   Fred Hutchinson Cancer Research Center;   Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium;   National Cancer Institute (NCI)
Recruiting - verified January 2012

Conditions:   Non-Hodgkin's Lymphoma;   Leukemia;   Multiple Myeloma;   Myeloproliferative Disorder
Interventions:   Biological: thymoglobulin;   Biological: thymoglobulin
Sponsors:   Virginia Commonwealth University;   Virginia Commonwealth University;   Genzyme
Recruiting - verified January 2012

Conditions:   Acute Myeloid Leukemia;   Myelodysplastic Syndrome;   Acute Lymphocytic Leukemia;   Relapsed/Refractory Chronic Lymphocytic Leukemia;   Relapsed/Refractory Non Hodgkin's Lymphoma;   Hodgkins Disease;   Relapsed Refractory Multiple Myeloma
Interventions:   Drug: Antithymocyte Globulin;   Drug: Clofarabine;   Drug: Clofarabine;   Drug: Clofarabine
Sponsors:   Dana-Farber Cancer Institute;   Beth Israel Deaconess Medical Center;   Genzyme
Recruiting - verified February 2012

Conditions:   Leukemia;   Lymphoma;   Bone Marrow Failure;   Immunodeficiencies;   Histiocytosis
Interventions:   Drug: Full Intensity with TBI;   Drug: Full Intensity;   Drug: Reduced Intensity;   Drug: Reduced Intensity (Fanconi)
Sponsors:   New York Medical College;   New York Medical College
Recruiting - verified April 2012

Conditions:   Non-Hodgkin's Lymphoma;   Hodgkins Disease
Interventions:   Drug: Fludarabine and Busulfan;   Drug: Fludarabine, Busulfan and ATG
Sponsors:   Columbia University;   Columbia University;   Duke University
Recruiting - verified January 2012

Condition:   Fanconi Anemia
Interventions:   Biological: anti-thymocyte globulin;   Drug: cyclophosphamide;   Drug: fludarabine phosphate;   Procedure: hematopoietic stem cell transplantation;   Drug: methylprednisolone;   Drug: filgrastim;   Drug: cyclosporine;   Drug: Mycophenolate Mofetil
Sponsors:   Masonic Cancer Center, University of Minnesota;   Masonic Cancer Center, University of Minnesota
Recruiting - verified December 2011

Condition:   Cancer
Interventions:   Biological: anti-thymocyte globulin;   Biological: rituximab;   Drug: clofarabine;   Procedure: stem cell transplantation
Sponsors:   Masonic Cancer Center, University of Minnesota;   Masonic Cancer Center, University of Minnesota
Recruiting - verified January 2012

Conditions:   Acute Myeloid Leukemia;   Advanced Myelodysplastic Syndromes
Intervention:   Drug: Busulfan, Melphalan, Fludarabine, Anti-Thymocyte Globulin, Palifermin, Stem cell transplant
Sponsors:   Memorial Sloan-Kettering Cancer Center;   Memorial Sloan-Kettering Cancer Center
Recruiting - verified November 2011

Conditions:   Acute Myeloid Leukemia;   Acute Lymphoblastic Leukemia;   Myelodysplasia;   Chronic Myeloid Leukemia
Interventions:   Radiation: Total Body Irradiation;   Drug: Thiotepa;   Drug: Fludarabine;   Biological: Rabbit ATG;   Drug: Palifermin
Sponsors:   Indiana University;   Indiana University
Recruiting - verified January 2012

Conditions:   Myelodysplastic Syndrome;   Leukemia
Interventions:   Procedure: Cord Blood Infusion;   Drug: Busulfan;   Drug: Fludarabine;   Drug: Rituximab;   Other: ATG;   Drug: Cyclophosphamide;   Drug: Clofarabine;   Radiation: Total Body Irradiation (TBI);   Drug: Melphalan
Sponsors:   M.D. Anderson Cancer Center;   M.D. Anderson Cancer Center
Recruiting - verified May 2012

Condition:   Lymphoma, Non-Hodgkin
Interventions:   Drug: Cyclophosphamide;   Drug: Carmustine;   Drug: Etoposide;   Drug: Filgrastim;   Drug: Antithymocyte globulin;   Drug: Cyclosporine;   Drug: Mycophenolate mofetil;   Drug: rituximab
Sponsors:   Stanford University;   Stanford University
Recruiting - verified January 2012

Condition:   Aplastic Anemia
Interventions:   Drug: Antithymocyte Globulin;   Drug: Cyclophosphamide;   Drug: Fludarabine;   Radiation: Total Body Irradiation (TBI);   Procedure: Bone Marrow Transplant
Sponsors:   M.D. Anderson Cancer Center;   M.D. Anderson Cancer Center;   National Heart, Lung, and Blood Institute (NHLBI);   National Cancer Institute (NCI)
Recruiting - verified April 2012

Condition:   Type 1 Diabetes Mellitus
Intervention:   Procedure: Islet transplant
Sponsors:   National Institute of Allergy and Infectious Diseases (NIAID);   National Institute of Allergy and Infectious Diseases (NIAID);   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Recruiting - verified December 2011

Conditions:   Dyskeratosis Congenita;   Aplastic Anemia
Interventions:   Drug: Campath 1H;   Drug: Cyclophosphamide;   Drug: Fludarabine;   Procedure: Total Body Irradiation;   Procedure: Stem Cell Transplantation;   Drug: ATG
Sponsors:   Masonic Cancer Center, University of Minnesota;   Masonic Cancer Center, University of Minnesota
Recruiting - verified March 2012

Conditions:   Myelodysplastic Syndrome;   Leukemia
Interventions:   Drug: Thymoglobulin;   Drug: Busulfan;   Drug: Fludarabine
Sponsors:   M.D. Anderson Cancer Center;   M.D. Anderson Cancer Center
Recruiting - verified March 2012

Condition:   Hodgkin's Disease
Interventions:   Drug: Gemcitabine;   Drug: Fludarabine;   Drug: Melphalan;   Drug: Antithymocyte Globulin;   Procedure: Allogeneic Stem Cell Infusion
Sponsors:   M.D. Anderson Cancer Center;   M.D. Anderson Cancer Center
Recruiting - verified May 2012

Condition:   Fanconi Anemia
Interventions:   Drug: Cyclophosphamide;   Drug: Fludarabine;   Drug: anti-thymocyte globulin (ATG);   Procedure: Total Body Irradiation;   Procedure: Bone Marrow Transplantation;   Drug: Mycophenolate Mofetil;   Drug: Methylprednisolone
Sponsors:   Masonic Cancer Center, University of Minnesota;   Masonic Cancer Center, University of Minnesota
Recruiting - verified April 2012

Condition:   Kidney Transplantation
Intervention:   Procedure: Kidney transplantation
Sponsors:   Stanford University;   Stanford University;   National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified November 2011

Conditions:   Myeloproliferative Disorders;   Leukemia;   Lymphoma;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes
Interventions:   Biological: anti-thymocyte globulin;   Drug: cyclophosphamide;   Drug: cyclosporine;   Drug: fludarabine phosphate;   Drug: mycophenolate mofetil;   Procedure: umbilical cord blood transplantation;   Radiation: total-body irradiation
Sponsors:   Masonic Cancer Center, University of Minnesota;   Masonic Cancer Center, University of Minnesota
Recruiting - verified December 2011

Conditions:   Kidney Cancer;   Leukemia;   Lymphoma;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes
Interventions:   Biological: anti-thymocyte globulin;   Drug: cyclophosphamide;   Drug: cyclosporine;   Drug: fludarabine phosphate;   Drug: mycophenolate mofetil;   Procedure: stem cell transplantation;   Radiation: total-body irradiation;   Drug: methylprednisolone;   Drug: allopurinol;   Drug: filgrastim
Sponsors:   Masonic Cancer Center, University of Minnesota;   Masonic Cancer Center, University of Minnesota
Recruiting - verified April 2012

Condition:   Fanconi Anemia
Interventions:   Biological: anti-thymocyte globulin;   Biological: filgrastim;   Drug: busulfan;   Drug: cyclophosphamide;   Drug: fludarabine phosphate;   Drug: methylprednisolone;   Biological: Hematopoietic stem cell transplantation
Sponsors:   Masonic Cancer Center, University of Minnesota;   Masonic Cancer Center, University of Minnesota
Recruiting - verified April 2012

Conditions:   Myeloproliferative Disorders;   Blood Cancer;   Myelodysplastic Syndromes
Interventions:   Procedure: Total Lymphoid Irradiation (TLI);   Procedure: Anti-Thymocyte Globulin as Conditioning
Sponsors:   Stanford University;   Stanford University;   National Institutes of Health (NIH)
Recruiting - verified January 2012

Conditions:   Sickle Cell Disease;   Thalassemia;   Severe Congenital Neutropenia;   Diamond-Blackfan Anemia;   Shwachman-Diamond Syndrome
Interventions:   Drug: Busulfan, Fludarabine, ATG, TLI;   Drug: Busulfan, Cyclophosphamide, ATG, GCSF;   Drug: Campath, Fludarabine, Cyclophosphamide;   Radiation: Total Body Irradiation;   Procedure: Stem cell infusion
Sponsors:   Masonic Cancer Center, University of Minnesota;   Masonic Cancer Center, University of Minnesota;   National Marrow Donor Program
Recruiting - verified April 2012

Conditions:   Leukemia, Lymphocytic, Acute;   AML;   MDS
Interventions:   Procedure: Stem Cell Transplant;   Drug: Busulfan, Cyclophosphamide, Melphalan, G-CSF, ATG
Sponsors:   Masonic Cancer Center, University of Minnesota;   Masonic Cancer Center, University of Minnesota
Recruiting - verified November 2011

Conditions:   Hemophagocytic Lymphohistiocytosis;   X-Linked Lymphoproliferative Disorders;   Chediak-Higashi Syndrome;   Griscelli Syndrome;   Immunologic Deficiency Syndromes;   Langerhans-Cell Histiocytosis
Interventions:   Procedure: Stem Cell Transplant;   Drug: Fludarabine, melphalan, ATG or Campath
Sponsors:   Masonic Cancer Center, University of Minnesota;   Masonic Cancer Center, University of Minnesota
Recruiting - verified April 2012

Conditions:   Childhood Langerhans Cell Histiocytosis;   Fanconi Anemia;   Leukemia;   Lymphoma;   Myelodysplastic Syndromes;   Neuroblastoma;   Sarcoma;   Unspecified Childhood Solid Tumor, Protocol Specific
Interventions:   Biological: anti-thymocyte globulin;   Drug: busulfan;   Drug: cyclophosphamide;   Drug: fludarabine phosphate;   Drug: melphalan;   Drug: methylprednisolone;   Radiation: radiation therapy
Sponsors:   National Cancer Institute (NCI);   Milton S. Hershey Medical Center
Recruiting - verified October 2008

Conditions:   Chronic Myeloproliferative Disorders;   Leukemia;   Lymphoma;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Diseases;   Nonmalignant Neoplasm;   Unspecified Adult Solid Tumor, Protocol Specific;   Unspecified Childhood Solid Tumor, Protocol Specific
Interventions:   Biological: anti-thymocyte globulin;   Drug: busulfan;   Drug: carboplatin;   Drug: cyclophosphamide;   Drug: etoposide;   Drug: fludarabine phosphate;   Drug: melphalan;   Drug: thiotepa;   Radiation: total-body irradiation
Sponsors:   Roswell Park Cancer Institute;   Roswell Park Cancer Institute
Recruiting - verified December 2011